Nanollose Limited (NC6.AX)
AUD 0.02
(0.0%)
AUD 0.02
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -1.24 Million AUD | 1.78% |
| 2023 | -1.27 Million AUD | 13.14% |
| 2022 | -1.71 Million AUD | -44.72% |
| 2021 | -1.07 Million AUD | 31.74% |
| 2020 | -1.59 Million AUD | 21.23% |
| 2019 | -2.54 Million AUD | -20.22% |
| 2018 | -2.22 Million AUD | -132.33% |
| 2017 | -1.05 Million AUD | -8592.03% |
| 2016 | -3068.00 AUD | -353.71% |
| 2015 | -1048.00 AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -1.43 Million AUD | 7.01% |
| 2024 Q2 | -803.7 Thousand AUD | -58.78% |
| 2024 Q4 | -631.91 Thousand AUD | -2.27% |
| 2023 Q2 | -829.94 Thousand AUD | 0.0% |
| 2023 Q4 | -714.38 Thousand AUD | 0.0% |
| 2023 FY | -1.54 Million AUD | 13.14% |
| 2022 Q2 | -974.88 Thousand AUD | 0.0% |
| 2022 FY | -1.77 Million AUD | -44.72% |
| 2022 Q4 | -802.96 Thousand AUD | 0.0% |
| 2021 Q4 | -788.15 Thousand AUD | 0.0% |
| 2021 Q2 | -440.31 Thousand AUD | 0.0% |
| 2021 FY | -1.22 Million AUD | 31.74% |
| 2020 Q2 | -1.05 Million AUD | 0.0% |
| 2020 FY | -1.79 Million AUD | 21.23% |
| 2020 Q4 | -746.16 Thousand AUD | 0.0% |
| 2019 FY | -2.28 Million AUD | -20.22% |
| 2019 Q4 | -1.21 Million AUD | 0.0% |
| 2019 Q2 | -1.01 Million AUD | 0.0% |
| 2018 FY | -1.9 Million AUD | -132.33% |
| 2018 Q4 | -1.04 Million AUD | 0.0% |
| 2018 Q2 | -735.61 Thousand AUD | 0.0% |
| 2017 Q4 | -356.8 Thousand AUD | 0.0% |
| 2017 Q1 | -230.55 Thousand AUD | 0.0% |
| 2017 FY | -817.92 Thousand AUD | -8592.03% |
| 2017 Q3 | - AUD | 100.0% |
| 2017 Q2 | -461.1 Thousand AUD | -100.0% |
| 2016 FY | -9410.00 AUD | -353.71% |
| 2015 FY | -2074.00 AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 112.863% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 14.344% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 78.953% |
| Biome Australia Limited | -1.91 Million AUD | 34.675% |
| Patrys Limited | -3.53 Million AUD | 64.686% |
| Orthocell Limited | -11.68 Million AUD | 89.3% |
| Imugene Limited | -140.93 Million AUD | 99.113% |
| Noxopharm Limited | -7.53 Million AUD | 83.413% |
| PYC Therapeutics Limited | -38.85 Million AUD | 96.784% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 89.847% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 82.609% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 82.717% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 85.81% |
| CSL Limited | 5.64 Billion AUD | 100.022% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 82.625% |
| Bio-Gene Technology Limited | -3.06 Million AUD | 59.189% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 102.543% |
| Starpharma Holdings Limited | -15.15 Million AUD | 91.755% |
| Memphasys Limited | -2.7 Million AUD | 53.779% |
| Invex Therapeutics Ltd | -2.13 Million AUD | 41.423% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | 39.227% |
| Amplia Therapeutics Limited | -4.42 Million AUD | 71.755% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 91.498% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | 56.509% |
| Race Oncology Limited | -13.38 Million AUD | 90.659% |
| Nyrada Inc. | -4.56 Million AUD | 72.594% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 95.013% |
| PharmAust Limited | -6.65 Million AUD | 81.23% |
| Immutep Limited | -44.93 Million AUD | 97.219% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 97.21% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 93.624% |
| BTC Health Limited | 1.05 Million AUD | 218.435% |
| Acrux Limited | -9.83 Million AUD | 87.291% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 100.553% |
| Biotron Limited | -5.15 Million AUD | 75.737% |
| Tissue Repair Ltd | -4.87 Million AUD | 74.368% |
| AdAlta Limited | -5.26 Million AUD | 76.246% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 97.353% |
| Hexima Limited | -1 Million AUD | -23.898% |
| AnteoTech Limited | -11.72 Million AUD | 89.342% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 98.081% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 94.332% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 72.766% |
| Actinogen Medical Limited | -12.83 Million AUD | 90.265% |
| Immuron Limited | -5.8 Million AUD | 78.455% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 77.962% |